Medications not intended for treatment of dyslipidemias and with a variable effect on lipids

Current Pharmaceutical Design

Volumn 20, Issue 40, 2014, Pages 6325-6338

  Whayne, Thomas F ^a   Mukherjee, Debabrata ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antipsychotic medications; Cardiovascular; Diabetes mellitus; Dyslipidemia; Estrogen; Human immunodeficiency virus infection

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANASTROZOLE; ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYCLOSPORIN; DERMATOLOGICAL AGENT; DOXAZOSIN; ESTROGEN; EXEMESTANE; FLUOROURACIL; GLUCOCORTICOID; HUMAN GROWTH HORMONE; INSULIN; LETROZOLE; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PROPOFOL; RETINOIC ACID DERIVATIVE; RETINOID; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TAMOXIFEN; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TOREMIFENE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; CANCER THERAPY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; DYSLIPIDEMIA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LIPID BLOOD LEVEL; PRIORITY JOURNAL; PSORIASIS;

EID: 84963948810     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140620163023     Document Type: Article

References (186)

1. [1] Whayne TF, Jr. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology 2011; 62(5): 415-21.
2. [2] Mantel-Teeuwisse AK, Kloosterman JM, van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001; 24(6): 443-56.
3. [3] Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992; 267(7): 961-8.
4. [4] Whayne TF. What should medical practitioners know about the role of alternative medicines in cardiovascular disease management? Cardiovasc Ther 2010; 28(2): 106-23.
5. [5] Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78(8): 965-78.
6. [6] Wright C, Zielke J, Whayne TF. Policosanol, an aliphatic alcohol sugarcane derivative: Use in patients intolerant of or inadequately responsive to statin therapy. Int J Angiol 2005; 13: 173-5.
7. [7] Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002; 143(2): 356-65.
8. [8] Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003; 290(6): 765-72.
9. [9] Ulbricht C, Basch E, Szapary P, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005; 13(4): 279-90.
10. [10] Lilley JS, Linton MF, Fazio S. Oral retinoids and plasma lipids. Dermatol Ther 2013; 26(5): 404-10.
11. [11] Estrada V, Portilla J. Dyslipidemia related to antiretroviral therapy. AIDS Rev 2011; 13(1): 49-56.
12. [12] Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007; 7(12): 787-96.
13. [13] Garg H, Joshi A, Mukherjee D. Cardiovascular complications of HIV infection and treatment. Cardiovasc Hematol Agents Med Chem 2013; 11(1): 58-66.
14. [14] Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8(5): 280-7.
15. [15] El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviralnaive cohort. HIV Med 2005; 6(2): 114-21.
16. [16] Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48(5): 590-8.
17. [17] Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care 2006; 18(2): 149-57.
18. [18] Liu Y, Nguyen P, Baris TZ, Poirier MC. Molecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs). Cardiovasc Toxicol 2012; 12(2): 123-34.
19. [19] Hurlimann D, Weber R, Enseleit F, Luscher TF.HIV infection, antiretroviral therapy, and endothelium. Herz 2005; 30(6): 472-80.
20. [20] Rabi SA, Laird GM, Durand CM, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 2013; 123(9): 3848-60.
21. [21] Carr A. Cardiovascular risk factors in HIV-infected patients. J Acquired Immune Deficiency Syndromes 2003; 34 Suppl 1: S73-8.
22. [22] Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351(9119): 1881-3.
23. [23] Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet 1998; 351(9117): 1736.
24. [24] Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353(9170): 2093-9.
25. [25] Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100(7): 700-5.
26. [26] Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. Current Opinion in Lipidology 2007; 18(5): 561-5.
27. [27] Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Progress in Lipid Research 2003; 42(2): 81-92.
28. [28] Parker RA, Flint OP, Mulvey R, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Molecular Pharmacology 2005; 67(6): 1909-19.
29. [29] De Barros S, Zakaroff-Girard A, Lafontan M, Galitzky J, Bourlier V. Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J Pharmacol Exp Therapeut 2007; 320(1): 291-9.
30. [30] Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62(18): 5230-5.
31. [31] Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biological Chem 1999; 274(50): 35734-40.
32. [32] Murata H, Hruz PW, Mueckler M. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr Drug Targets Infect Disord 2002; 2(1): 1-8.
33. [33] Coffinier C, Hudon SE, Farber EA, et al. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci USA 2007; 104(33): 13432-7.
34. [34] Goulbourne CN, Vaux DJ. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy? Biochemical Society Transactions 2010; 38(Pt 1): 292-6.
35. [35] Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Med 2001; 7(12): 1327-31.
36. [36] Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clinical Investigation 2003; 111(3): 389-97.
37. [37] Cianflone K, Zakarian R, Couillard C, Delplanque B, Despres JP, Sniderman A. Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J Lipid Res 2004; 45(1): 124-31.
38. [38] Jiang B, Hebert VY, Zavecz JH, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquired Immune Deficiency Syndromes 2006; 42(4): 391-5.
39. [39] Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquired Immune Deficiency Syndromes 2005; 40(1): 12-9.
40. [40] Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30(1): 113-9.
41. [41] Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24(3): 427-35.
42. [42] Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52(7): 1695-700.
43. [43] Vyas AK, Koster JC, Tzekov A, Hruz PW. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biological Chem 2010; 285(47): 36395-400.
44. [44] Nitta K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin Exp Nephrol 2012; 16(4): 522-9.
45. [45] Ligabue G, Cavazzini F, Albertazzi A. Dyslipidemia and the risk of kidney disease. G Ital Nefrol 2007; 24 38: 8-12.
46. [46] McKay GJ, Savage DA, Patterson CC, Lewis G, McKnight AJ, Maxwell AP. Association analysis of dyslipidemia-related genes in diabetic nephropathy. PLoS One 2013; 8(3): e58472.
47. [47] Montford JR, Chonchol M, Cheung AK, et al. Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23. Am J Nephrol 2013; 37(3): 183-90.
48. [48] Chmielewski M, Verduijn M, Drechsler C, et al. Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding? Nephrol Dial Transplant 2011; 26(10): 3325-31.
49. [49] Maharjan N, Bedi U, Arora R, Bhandari S, Dahal P, Khosla S. Impact of statins on cardiovascular outcomes in renal transplant recipients: a systematic review. Am J Ther 2011; 18(3): e48-54.
50. [50] Fabbian F, De Giorgi A, Pala M, Tiseo R, Manfredini R, Portaluppi F. Evidence-based statin prescription for cardiovascular protection in renal impairment. Clin Exp Nephrol 2011; 15(4): 456-63.
51. [51] Heymann EP, Kassimatis TI, Goldsmith DJ. Dyslipidemia, statins, and CKD patients' outcomes-review of the evidence in the postsharp era. J Nephrol 2012; 25(4): 460-72.
52. [52] Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012; 60(5): 747-69.
53. [53] Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157(4): 251-62.
54. [54] Balint A, Farkas K, Szucs M, et al. Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications. Scand J Gastroenterol 2014; 49(1): 59-65.
55. [55] Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6(2): 133-56.
56. [56] Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc Med J 2011; 5: 85-9.
57. [57] Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013; 6: 453-67.
58. [58] Mihailescu DV, Vora A, Mazzone T. Lipid effects of endocrine medications. Curr Atheroscler Rep 2011; 13(1): 88-94.
59. [59] Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52(2): 453-62.
60. [60] Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 2012; 1821(5): 819-25.
61. [61] Henderson SR, Maitland R, Mustafa OG, Miell J, Crook MA, Kottegoda SR. Severe hypertriglyceridaemia in Type 2 diabetes mellitus: beneficial effect of continuous insulin infusion. QJM 2013; 106(4): 355-9.
62. [62] Cole RP. Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. Arch Intern Med 2009; 169(15): 1439-41.
63. [63] Loo CC, Tan JY. Decreasing the plasma triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy: a case report. Am J Obstet Gynecol 2002; 187(1): 241-2.
64. [64] Sleth JC, Lafforgue E, Servais R, et al. A case of hypertriglycideremia-induced pancreatitis in pregnancy: value of heparin. Ann Fr Anesth Reanim 2004; 23(8): 835-7.
65. [65] Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320(16): 1060-8.
66. [66] Whayne TF, Jr., Felts JM, Harris PA. Effect of heparin on the inactivation of serum lipoprotein lipase by the liver in unanesthetized dogs. J Clin Invest 1969; 48(7): 1246-51.
67. [67] Whayne TF, Jr., Felts JM. Activation of lipoprotein lipase. Comparative study of man and other mammals. Circ Res 1970; 26(5): 545-51.
68. [68] Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276(1): 34-42.
69. [69] Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004; 89(1): 219-26.
70. [70] Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest 2003; 63(1): 45-53.
71. [71] Al Riyami NB, Frohlich J. Extreme hypertriglyceridemia following intravenous heparin infusion. Clin Biochem 2008; 41(10-11): 907-9.
72. [72] Whayne TF. Concerns about heparin therapy for hypertriglyceridemia. Arch Intern Med 2010; 170(1): 108-9; author reply 09.
73. [73] Zanchetti A. Overview and perspectives of antihypertensive treatment. Drugs 1990; 40 Suppl 4: 85-91.
74. [74] Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14(3): 203-9.
75. [75] Klein W. Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism). Z Kardiol 1992; 81(6): 295-302.
76. [76] Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77(6): 12b-16b.
77. [77] Ram CV. Beta-blockers in hypertension. Am J Cardiol 2010; 106(12): 1819-25.
78. [78] Sharp RP, Sirajuddin R, Sharief IM. Impact of carvedilol on the serum lipid profile. Ann Pharmacother 2008; 42(4): 564-71.
79. [79] Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The reninangiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302(6): H1219-30.
80. [80] Arao T, Okada Y, Mori H, Nishida K, Tanaka Y. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J 2013; 60(5): 563-70.
81. [81] Inoue T, Taguchi I, Abe S, Toyoda S, Sakuma M, Node K. Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. J Clin Pharm Ther 2011; 36(1): 103-10.
82. [82] Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, et al. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006; 47(1): 21-8.
83. [83] Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283(15): 1967-75.
84. [84] Leren TP, Berg K. Studies of serum lipids in hypercholesterolaemic rabbits treated with doxazosin. Scand J Clin Lab Invest 1988; 48(4): 313-7.
85. [85] Cao XB, Yang M, Wang RY, Ren LM. Effects of doxazosin and its enantiomers on serum lipid levels in rabbits fed by an atherogenic diet. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010; 26(2): 241-6.
86. [86] Hoogerbrugge N, de Groot E, de Heide LH, et al. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. Neth J Med 2002; 60(9): 354-61.
87. [87] Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75(5): 898-915.
88. [88] Carr MC, Knopp RH, Brunzell JD, et al. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care 2005; 28(7): 1555-61.
89. [89] Stojanovic ND, Kwong P, Byrne DJ, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54(4): 391-9.
90. [90] Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001; 76(1-5): 231-8.
91. [91] Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004; 48 Suppl 1: S30-40.
92. [92] Villanueva LA, Ortega R, Morimoto S, Villanueva S, Arranz C. Effects of tibolone on lipid and glucose metabolism as well as insulin secretion in postmenopausal women. Ginecol Obstet Mex 1999; 67: 473-7.
93. [93] Ostberg JE, Damjanovic T, Dimkovic N, Byrne D, Mikhailidis DP, Prelevic GM. Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertil Steril 2004; 81(6): 1624-31.
94. [94] Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77(5): 945-51.
95. [95] Naz F, Jyoti S, Akhtar N, Afzal M, Siddique YH. Lipid profile of women using oral contraceptive pills. Pak J Biol Sci 2012; 15(19): 947-50.
96. [96] Greenlund KJ, Webber LS, Srinivasan S, Wattigney W, Johnson C, Berenson GS. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa Heart Study. Ann Epidemiol 1997; 7(8): 561-7.
97. [97] Lee JY, Ku SY, Kim SH, Hwang SS, Lee HW, Park SM. Oral contraceptive use and measurable cardiovascular risk factors in Korean women aged 20-50 years: the Fourth Korean National Health and Nutrition Examination Survey 2007-2009 (KNHANES IV). Gynecol Endocrinol 2013; 29(7): 707-11.
98. [98] Kim K, Park H. Effect of oral contraceptive use on lipid profile in Korean women aged 35-55 years. Contraception 2012; 86(5): 500-5.
99. [99] Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, et al. Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. Br J Cancer 2013; 109(6): 1537-42.
100. [100] O'Regan RM, Gajdos C, Dardes RC, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002; 94(4): 274-83.
101. [101] Mao J, Yuan J, Wang L, et al. Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current. J Cell Physiol 2013; 228(5): 991-1001.
102. [102] Mikhailidis D, Ganotakis E, Georgoulias V, Vallance D, Winder A. Tamoxifen-induced hypertriglyceridaemia. Oncol Rep 1997; 4(3): 625-8.
103. [103] Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009; 35(2): 175-84.
104. [104] Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99(9): 727-37.
105. [105] Akhondi-Meybodi M, Mortazavy-Zadah MR, Hashemian Z, Moaiedi M. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab J Gastroenterol 2011; 12(1): 34-6.
106. [106] Chi F, Wu R, Zeng Y, Xing R, Liu Y, Xu Z. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis. Breast Cancer 2013; 20(2): 111-22.
107. [107] Tominaga T, Kimijima I, Kimura M, et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clin Oncol 2010; 40(7): 627-33.
108. [108] Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008; 26(11): 1824-9.
109. [109] Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Res Treat 2012; 136(3): 769-76.
110. [110] Hozumi Y, Suemasu K, Takei H, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan substudy. Ann Oncol 2011; 22(8): 1777-82.
111. [111] Markopoulos C, Dafni U, Misitzis J, et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res 2009; 11(3): R35.
112. [112] Markopoulos C, Polychronis A, Dafni U, et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol 2009; 20(1): 49-55.
113. [113] Kokshoorn NE, Biermasz NR, Roelfsema F, Smit JW, Pereira AM, Romijn JA. GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 2011; 164(5): 657-65.
114. [114] Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJ, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci U S A 1981; 78(4): 2591-5.
115. [115] Pykalisto O, Goldberg AP, Brunzell JD. Reversal of decreased human adipose tissue lipoprotein lipase and hypertriglyceridemia after treatment of hypothyroidism. J Clin Endocrinol Metab 1976; 43(3): 591-600.
116. [116] O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68(9): 860-6.
117. [117] Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 2007; 92(2): 608-11.
118. [118] Chock B, Lin TC, Li CS, Swislocki A. Plasma testosterone is associated with Framingham risk score. Aging Male 2012; 15(3): 134-9.
119. [119] Anawalt BD, Hotaling JM, Walsh TJ, Matsumoto AM. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol 2012; 187(4): 1369-73.
120. [120] Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: The lipid link. Vascul Pharmacol 2009; 51(5-6): 303-13.
121. [121] Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82(1): 29-39.
122. [122] Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63(3): 280-93.
123. [123] Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111(4): 261-9.
124. [124] Wan ZH, Wen YB, Ding QF, Xu TY. Effects of testosterone substitution on metabolic syndrome-related factors in hypogonadal males: a meta-analysis. Zhonghua Nan Ke Xue 2010; 16(6): 510-5.
125. [125] Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93(6): 2042-9.
126. [126] Whitehead M. Progestins and androgens. Fertil Steril 1994; 62(6): 161S-67S.
127. [127] Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA, Kenny AM. Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. Age Ageing 2010; 39(4): 451-8.
128. [128] Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 2010; 106(6): 893-901.
129. [129] Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med 2008; 5(4): 765-76.
130. [130] Fardet L. Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy. Rev Med Interne 2013; 34(5): 303-9.
131. [131] Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011; 40(2): 409-17.
132. [132] Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16(4): 505-11.
133. [133] Hansel B, Bruckert E. Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy. Ann Endocrinol (Paris) 2010; 71(4): 257-63.
134. [134] Kanat M, Sipahioglu M, Arinc H, Serin E, Yildiz O, Tunckale A, et al. Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones? Med Hypotheses 2007; 69(1): 104-12.
135. [135] Weissman E, Jackson C, Scholer N, Goetz R, Essock S. Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication. Clin Schizophr Relat Psychoses 2012; 5(4): 201-7.
136. [136] Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163(10): 1821-5.
137. [137] Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapineinduced elevation of plasma triglyceride levels. Am J Psychiatry 1999; 156(9): 1471-2.
138. [138] Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21(4): 369-74.
139. [139] Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 2011; 51(5): 631-8.
140. [140] Feng S, Melkersson K. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine. Neuro Endocrinol Lett 2012; 33(5): 493-8.
141. [141] Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1: 1-93.
142. [142] Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 2005; 6(3): 148-57.
143. [143] Berk M, Fitzsimons J, Lambert T, et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs 2007; 21(2): 117-27.
144. [144] Chiang HL, Liu CC, Hwang TJ. Rapid dose-dependent effect of clozapine on a schizophrenic patient's lipid profile. J Psychopharmacol 2009; 23(4): 465-7.
145. [145] Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull 2013; 39(2): 306-18.
146. [146] Contreras-Shannon V, Heart DL, Paredes RM, et al. Clozapineinduced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One 2013; 8(3): e59012.
147. [147] Lally J, Gallagher A, Bainbridge E, Avalos G, Ahmed M, McDonald C. Increases in triglyceride levels are associated with clinical response to clozapine treatment. J Psychopharmacol 2013; 27(4): 401-3.
148. [148] Ahmed M, Griffin D, O'Toole R, McDonald C. Clozapine-induced severe mixed hyperlipidemia: a case report. Gen Hosp Psychiatry 2009; 31(1): 93-6.
149. [149] Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66(9): 1116-21.
150. [150] Caniato RN, Alvarenga ME, Garcia-Alcaraz MA. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust N Z J Psychiatry 2006; 40(8): 691-7.
151. [151] eder-Ischia U, Ebenbichler C, Fleischhacker WW. Olanzapineinduced weight gain and disturbances of lipid and glucose metabolism. Essent Psychopharmacol 2005; 6(2): 112-7.
152. [152] Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60(11): 767-70.
153. [153] Ball MP, Hooper ET, Skipwith DF, Cates ME. Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy. Ann Pharmacother 2005; 39(9): 1570-2.
154. [154] Devaud JC, Berger MM, Pannatier A, et al. Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness. Intensive Care Med 2012; 38(12): 1990-8.
155. [155] Mittendorfer B, Ostlund RE, Jr., Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9(10): 599-604.
156. [156] Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations. Aliment Pharmacol Ther 2004; 19(11): 1173-9.
157. [157] Blackett P, Tryggestad J, Krishnan S, et al. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol 2013; 7(2): 132-9.
158. [158] Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther 2012; 37(2): 187-95.
159. [159] Derosa G, Maffioli P, Salvadeo SA, et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother 2010; 11(12): 1971-82.
160. [160] Ozkan Y, Aydin S, Donder E, Koca SS, Ozkan B, Sahin I. Effect of orlistat on the total ghrelin and leptin levels in obese patients. J Physiol Biochem 2009; 65(3): 215-23.
161. [161] Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008; 9(18): 3151-8.
162. [162] Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91(8): 961-4.
163. [163] Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87(7): 827-31.
164. [164] Veerman JL, Barendregt JJ, Forster M, Vos T. Cost-effectiveness of pharmacotherapy to reduce obesity. PLoS One 2011; 6(10): e26051.
165. [165] Bar-Sela G, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemother Pharmacol 2009; 63(5): 779-82.
166. [166] Duman BB, Paydas S, Tetiker T, et al. Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases. Pharmacology 2012; 90(3-4): 212-5.
167. [167] Seminara P, Losanno T, Emiliani A, Manna G. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? Cardiology 2010; 116(1): 42-4.
168. [168] Michie CO, Sakala M, Rivans I, Strachan MW, Clive S. The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 2010; 103(5): 617-21.
169. [169] Geva S, Lazarev I, Geffen DB, Ariad S. Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine. J Chemother 2013; 25(3): 176-80.
170. [170] Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG, Karayiannacos PE. Influence of 5-fluorouracil on serum lipids. Acta Oncol 1995; 34(2): 253-6.
171. [171] Schneiders FL, van den Berg HP, Peters GJ, Verheul HM, van der Vliet HJ. Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. Med Oncol 2011; 28(4): 1136-9.
172. [172] Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35(3): 313-24.
173. [173] Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169(5): 1066-70.
174. [174] Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18(4): 297-304.
175. [175] Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2013.
176. [176] Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013; 69(6): 1014-24.
177. [177] Saleh DA, Ismail MA, Ibrahim AM. Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci 2012; 15(2): 68-77.
178. [178] Jakubus T, Michalska-Jakubus M, Lukawski K, Janowska A, Czuczwar SJ. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep 2009; 61(3): 411-23.
179. [179] Mania M, Kasradze S, Okujava N. Valproic Acid related metabolic syndrome in patients with epilepsy. Georgian Med News 2011(194): 43-7.
180. [180] Kim DW, Lee SY, Shon YM, Kim JH. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia 2013; 54(10): e146-9.
181. [181] Sankar R. Initial treatment of epilepsy with antiepileptic drugs: pediatric issues. Neurology 2004; 63(10): S30-9.
182. [182] Luoma PV, Myllyla VV, Sotaniemi EA, Lehtinen IA, Hokkanen EJ. Plasma high-density lipoprotein cholesterol in epileptics treated with various anticonvulsants. Eur Neurol 1980; 19(1): 67-72.
183. [183] Pita-Calandre E, Rodriguez-Lopez CM, Cano MD, Pena-Bernal M. Serum lipids. lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or phenytoin. Rev Neurol 1998; 27(159): 785-9.
184. [184] Niedzielska K, Rosnowska M, Wehr H. The HDL cholesterol level in patients treated with antiepileptic drugs. Neurol Neurochir Pol 1989; 23(3): 193-7.
185. [185] Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997; 33(3): 242-5.
186. [186] Stone N, Robinson J, Lichenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol (2013), doi: 10.1016/jjacc.2013.11002